Latest Ratios: P/E Ratio -17.0x · EV/EBITDA N/A · ROE -22.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $291M | $203M | $390M | $119M | $158M | $574M | — | — |
| Enterprise Value | $300M | $212M | $417M | $121M | $158M | $498M | — | — |
| P/E Ratio → | -16.97 | — | — | — | — | — | — | — |
| P/S Ratio | 7.18 | 5.02 | 10.34 | 3.24 | 3.82 | 15.55 | — | — |
| P/B Ratio | 4.22 | 2.96 | 4.74 | 1.32 | 1.59 | 4.01 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.24 | 11.04 | 3.29 | 3.83 | 13.50 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.2% | 33.2% | 19.2% | 28.1% | 42.2% | 47.8% | 56.7% | 42.7% |
| Operating Margin | -41.9% | -41.9% | -69.3% | -96.9% | -119.9% | -32.5% | 14.9% | -9.2% |
| Net Profit Margin | -42.6% | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% | 11.4% | -6.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -22.8% | -22.8% | -31.0% | -38.7% | -39.1% | -10.0% | 10.9% | -10.1% |
| ROA | -15.5% | -15.5% | -21.6% | -26.2% | -29.8% | -8.5% | 5.9% | -2.2% |
| ROIC | -13.6% | -13.6% | -19.5% | -27.8% | -44.5% | -15.4% | 12.1% | -15.8% |
| ROCE | -16.7% | -16.7% | -23.0% | -27.2% | -33.1% | -11.0% | 8.3% | -3.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.37 | 0.34 | 0.42 | 0.08 | — | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.13 | 0.32 | 0.02 | 0.00 | -0.53 | -0.06 | -0.32 |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.49 | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -23.23 | -23.23 | -38.06 | -37.45 | — | -20.39 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.58 | 4.58 | 3.82 | 5.14 | 5.62 | 13.07 | 4.14 | 2.76 |
| Quick Ratio | 3.64 | 3.64 | 3.21 | 3.84 | 4.50 | 12.37 | 3.24 | 2.30 |
| Cash Ratio | 0.78 | 0.78 | 2.71 | 3.21 | 3.88 | 11.30 | 1.29 | 1.73 |
| Asset Turnover | — | 0.39 | 0.32 | 0.29 | 0.27 | 0.22 | 0.50 | 0.34 |
| Inventory Turnover | 3.84 | 3.84 | 4.49 | 2.28 | 1.96 | 3.57 | 3.78 | 4.49 |
| Days Sales Outstanding | — | 41.60 | 41.70 | 39.28 | 37.74 | 57.92 | 76.61 | 54.24 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $53M | $47M | $32M | $28M | $28M | $4M | $4M |
Imminent liquidity and dilution
According to current market data, TKNO trades at a 7.61x price-to-sales multiple, a valuation that appears disconnected from the company's negative operating margins and the significant liquidity risks highlighted in recent SEC filings, suggesting investors are pricing in speculative long-term growth rather than current fundamental performance.
The absence of a positive P/E ratio and the reliance on a revenue-based multiple indicate that the market is valuing the firm as a high-risk option on future bioprocessing demand. This valuation level warrants caution, as it implies a growth trajectory that the company's recent 7.35% revenue expansion has yet to validate.
Based on reported financial statements, TKNO's ROIC has remained consistently negative over the last ten quarters, bottoming at -8.6% in 2023Q4 and showing little evidence of improvement, which suggests that the company's heavy capital investments in the Hollister facility are currently failing to generate economic value.
The negative ROIC trend reflects a structural inability to achieve the necessary scale to offset the high fixed costs associated with its manufacturing infrastructure. Investors should monitor whether future capacity utilization can reverse this trend, though current data suggests a continued decay in capital efficiency.
As reported in quarterly filings, the company's cash conversion cycle remains elevated, fluctuating between 109 and 195 days, which indicates significant inefficiencies in managing inventory and receivables compared to the leaner operational standards typically observed in the broader specialty drug manufacturing sector.
The high days-inventory-outstanding (DIO) suggests that the company may be struggling with product obsolescence or over-production relative to current demand. This inefficiency ties up critical liquidity, further exacerbating the company's precarious cash position and limiting its operational flexibility.
Based on the most recent quarterly data, the company's cash and equivalents have dwindled to $5.9 million, a figure that appears insufficient given the ongoing operating losses, signaling that the firm may face a liquidity crunch that necessitates immediate external financing or strategic intervention.
While the current ratio of 4.59 might appear healthy in isolation, it is heavily skewed by inventory levels that may not be easily liquidated. The rapid depletion of cash reserves suggests that the company's ability to fund its operations without dilutive capital raises is increasingly limited.
The most commonly misapplied metric for TKNO is the price-to-sales ratio, which obscures the company's underlying cash burn and the high probability of shareholder dilution, failing to account for the fact that revenue growth is currently insufficient to cover the firm's massive fixed-cost overhead.
Analysts should instead focus on the cash-burn-to-liquidity ratio, which provides a more accurate assessment of the company's survival horizon. Relying on revenue multiples in this context ignores the reality that the company's current business model is not yet self-sustaining.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TKNO stock.
Alpha Teknova, Inc.'s current P/E ratio is -17.0x. This places it at the 50th percentile of its historical range.
Alpha Teknova, Inc.'s return on equity (ROE) is -22.8%. The historical average is -20.1%.
Based on historical data, Alpha Teknova, Inc. is trading at a P/E of -17.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Alpha Teknova, Inc. has 33.2% gross margin and -41.9% operating margin.